DPP4 and type 2 diabetes mellitus: Incretin-related drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, lower blood glucose in patients with type 2 diabetes through a transient glucose-dependent stimulation of insulin and suppression of glucagon secretion [11].